- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
EFFECT OF THE SHORT-TERM ANCHUSAN TREATMENT ON CYP3A4-MEDIATED MIDAZOLAM METABOLISM IN HEALTHY SUBJECTS
-
- SAMBE Takehiko
- Department of Pharmacology, Showa University School of Medicine
-
- TOSHIMA Hirokazu
- Department of Pharmacology, Showa University School of Medicine
-
- RYU Kakei
- Department of Pharmacology, Showa University School of Medicine
-
- KOBAYASHI Yoshito
- Department of Pharmacology, Showa University School of Medicine
-
- KONDO Yasuyuki
- Department of Pharmacology, Showa University School of Medicine
-
- OGUCHI Katsuji
- Department of Pharmacology, Showa University School of Medicine
-
- NISHIMURA Yuki
- Department of Pharmacology, Showa University School of Medicine
-
- UCHIDA Naoki
- Department of Pharmacology, Showa University School of Medicine
-
- IWASE Mariko
- Department of Pharmacology, Showa University School of Medicine
-
- HARIMOTO Yoshie
- Department of Pharmacology, Showa University School of Medicine
-
- KAWAKAMI Momoko
- Department of Pharmacology, Showa University School of Medicine
-
- KOBAYASHI Shinichi
- Department of Pharmacology, Showa University School of Medicine
Bibliographic Information
- Other Title
-
- 安中散短期投与のミダゾラム代謝に及ぼす影響
- アンチュウサンタンキ トウヨ ノ ミダゾラム タイシャ ニ オヨボス エイキョウ
Search this article
Description
In Japan, many medical doctors utilize Kampo medicine in their daily practice in combination with Western medicine. However, there have been few reports investigating the drug-drug interactions via cytochrome P450 (CYP) between these medicines. In our previous study, long-term administration of anchusan increased the serum midazolam (MDZ) concentrations in rats and humans, suggesting the inhibition of intestinal CYP3A likely caused by the metabolites of anchusan constituents. To clarify the property of this effect, we conducted a short-term anchusan treatment study in human and investigated its effect on MDZ metabolism. The open-label, fixed-sequence, 2 period study was performed in 12 healthy men who were divided into two groups A and B. Each subject was administered 7.5mg MDZ orally as a control trial prior to the anchusan treatments. MDZ was administered again after either 2 hours (Group A) or 16 hours (Group B) of three times 2.5g anchusan treatments. Serial blood samples were collected over 8 hours after each MDZ dose. The serum MDZ concentrations were analyzed by HPLC and its pharmacokinetic parameters were determined. The visual analogue scale (VAS) was used for the estimation of the sedative effect. The short-term anchusan treatment did not show any remarkable change in MDZ pharmacokinetics (AUC0-8, Cmax and t1/2), although a statistically significant but minor decrease of AUC0-8 was observed after anchusan treatment in Group B. The VAS score showed a similar value between before and after anchusan treatment in both groups. The results showed that short-term (3 times) anchusan treatment did not inhibit MDZ pharmacokinetics and pharmacological effect, when MDZ was administered 2 or 16 hours after the last anchusan dose. CYP3A-mediated drug interaction caused by short-term anchusan does not occur under this condition.
Journal
-
- Journal of The Showa University Society
-
Journal of The Showa University Society 73 (2), 67-75, 2013
The Showa University Society
- Tweet
Details 詳細情報について
-
- CRID
- 1390282680719587840
-
- NII Article ID
- 130004730562
-
- NII Book ID
- AA12635661
-
- ISSN
- 2188529X
- 2187719X
-
- NDL BIB ID
- 025023753
-
- Text Lang
- ja
-
- Article Type
- departmental bulletin paper
-
- Data Source
-
- JaLC
- IRDB
- NDL Search
- CiNii Articles
-
- Abstract License Flag
- Disallowed